CClinicalTrials.gg
WithdrawnNCT02140879LAMBSUpdated Sep 15, 2022

LA Moms and Babies Study (LAMBS) for Nutrition and Growth

An interventional study of Capsule 1 or Capsule 2 and Capsule 2 in Pregnancy and Inflammation, sponsored by Pennington Biomedical Research Center. Withdrawn at 1 site in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-15.

Sponsored by Pennington Biomedical Research Center · Not applicable, Interventional, and Basic science

Why this study was withdrawn
IRB closed on 9/5/2018
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

This research study will examine how diet during pregnancy can benefit pregnancy and pregnancy outcome, such as your baby's weight. More specifically, the investigators will study the effects of two different food oils/fats that are commonly consumed to determine if one is more effective in limiting maternal inflammation during pregnancy. You are being asked to take part in this study because it will help us update and make the best dietary recommendations for pregnant women and women of child bearing ages.

Read the detailed description

Pregnant women will be asked to consume dietary supplements (2 capsules, from the Pennington Biomedical Pharmacy) each day during pregnancy. They will begin taking the capsules around 17 weeks of pregnancy and take them each day until their babies are born. Women will be randomized to one of two groups. Randomization means they will be put into a group by chance, similar to flipping a coin. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. Neither the subject nor the study staff will know which group women are in.

Women will also keep a diary of how many capsules they take. At around 17, 22, 24, 26, 30, 32, and 36 weeks of pregnancy, women will go to Woman's Hospital to get new capsules and return any remaining capsules and their capsule diary. If they are not able to go to Woman's Hospital at weeks 22, 26, or 32 a researcher will arrange to meet them at an agreed upon prearranged place, such as a pharmacy, a library, or Pennington Biomedical, for example. At the same visits to Woman's Hospital at weeks 17, 24, 30, and 36 weeks of pregnancy women will also have their blood drawn (approximately one tablespoon).

At 17, 22, 24, 26, 30, 32 and 36 weeks of pregnancy we will also ask women about the foods they are eating. We will do this by a prearranged phone call; women will not need to meet us in person for this.

Researchers will contact subjects weekly by phone to inquire about compliance with consumption of capsules. Contact will only take place during weeks in which a visit or phone call regarding diet is not required.

At 17, 24, 30, and 36 weeks of pregnancy small blood samples will be collected from their arm (approximately one tablespoon at each collection) for laboratory analyses. At the birth of their baby a sample of blood will be collected from the umbilical cord after their baby is delivered. All blood samples will be stored at Pennington Biomedical. Blood samples will be analyzed by the researchers who are involved in the study. Some analyses will take place at Pennington Biomedical and Louisiana State University (LSU). Deidentified (without subject names) samples will be sent to study researchers at Northeastern University in Boston, LSU Health Sciences Center in New Orleans, and DSM Nutritional Products in Columbia, Maryland for some of the analyses. At the end of the study remaining blood samples will be discarded unless women consent for their blood to be used for future research. Should women decide to withdraw from the study, any samples collected thus far will be included in the study since they will be deidentified and the investigators will not know which samples belong to each person. We will also collect information about the baby's birth weight, length, and health from the baby's hospital chart.

When the baby is 2 weeks, 6 months, and 12 months of age we will measure the baby's body fat and lean tissue. To do this measurement the baby will lie or sit in an enclosed chamber where the mother can see her baby during the measurements. There are no attachments made to the baby. At these times we will also determine the baby's body fat by measuring the thickness of the baby's skinfold; this is done by gently lifting a double fold of skin on the baby's hip, upper arm (triceps), and back of the thigh and measuring the thickness of that fold with a handheld instrument with two hinged arms that fit over the skinfold. There is no discomfort associated with this procedure. The measurements will be made at Woman's Hospital. During these visits we will also ask questions about how the mother is feeding her baby. Between these visits (when the baby is 2, 4, 8, and 10 months old) we will phone to ask about how the baby is being fed and to inquire about the mother's and baby's well-being.

02

Conditions studied

  • Pregnancy
  • Inflammation

Browse trials for

Keywords

  • pregnancy
  • inflammation
  • infant assessment
03

In context

Inflammation

3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.

Browse Inflammation studies →

Lead sponsor

Pennington Biomedical Research Center is the lead sponsor of 277 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Confirmed pregnancy
  • Caucasian/White and African-American ethnicities
  • Between the ages of 18 and 35 years
  • Overweight before becoming pregnant (BMI=25.0-29.9 kg/m2)
  • Pass on the glucose tolerance test for diabetes

Exclusion criteria

Exclusion Criteria:

  • Have more than 5 children
  • Have a history of high blood pressure, high blood lipids, kidney or liver disease
  • Have inability to handle blood sugar normally
  • Have polycystic ovary syndrome
  • Have thyroid disorder
  • Have multiple fetuses, pregnancy related complications (preterm labor; diagnosed with gestational diabetes mellitus, pregnancy impaired glucose tolerance, preeclampsia, a first degree relative with diabetes, gave birth to a previous large for gestational age infanthigh blood pressure, premature rupture of the membranes)
  • Have smoked in the past 6 months
  • Have been pregnant or lactating (breastfeeding) in the past year
  • Do not want their baby's body fat measured throughout the first year of life
  • Do not bring their prenatal record and study information copies to Woman's Hospital for delivery
  • Deliver at a hospital other than Woman's Hospital
  • Test positive for human immunodeficiency Virus (HIV), syphilis, sepsis, group B streptococcus, Hepatitis B
  • Do not follow study procedures
  • Planning to bank cord blood or unwilling to donate cord blood
  • Planned/elective C-section.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Capsule 1

    Placebo is a mixture of corn and soy oils.

    Dietary Supplement: Capsule 1 or Capsule 2 · Dietary Supplement: Capsule 2

  • Active comparator
    Capsule 2

    Active supplement group, will take capsules containing oil '2' which is an algal oil.

    Dietary Supplement: Capsule 1 or Capsule 2 · Dietary Supplement: Capsule 2

Interventions

  • Dietary supplementCapsule 1 or Capsule 2

    Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.

  • Dietary supplementCapsule 2

    Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .

06

What researchers measure

Primary outcomes

  1. Differences in maternal inflammation between the two study groups.

    Pregnancy creates a state of insulin resistance that is worsened by excess weight during pregnancy and it is accompanied by inflammation. Inflammation in pregnant women will be measured by a blood draw from the arm and analysis of the blood.

    Time frame: The Participant will be followed during pregnancy, between the 17th and 36th week of pregnancy, on average of 19 weeks.

Secondary outcomes

  1. Differences in infant growth will be determined with measurements of infant height and weight and with an instrument that determines air displaced by the baby's body.

    Measurements of the baby will be calculated in an enclosed chamber where the baby will lie on a tray in a bassinet-like crib with a plastic cover where the baby will be able to see his mother. There will be no attachments to the baby. At these time periods the baby's body fat will also be measured by the thickness of the baby's skinfold; this is done by gently lifting a double fold of skin on the baby's hip, upper arm (triceps), and back of the thigh and measuring the thickness of that fold with a handheld instrument with two hinged arms that fit over the skinfold. There is no discomfort associated with this procedure.

    Time frame: The participant will be followed the First year of life, an expected average of 52 weeks.

07

Study locations

1 site
  • Womans Hospital
    Baton Rouge, Louisiana 70803, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02140879
Lead sponsor
Pennington Biomedical Research Center
Collaborators
United States Department of Agriculture (USDA)
Responsible party
Sponsor
First posted
May 16, 2014
Start date
Apr 2014
Primary completion
Apr 2016
Completion
Aug 2017
Last update
Sep 15, 2022

Study contacts

Carol J Lammi-Keefe, PhD, RD
principal investigator · PBRC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion